10 tablets
Rybelsus 3 — Semaglutide 3 mg, 10 pcs, Novo Nordisk

Rybelsus 3 mg (Semaglutide) 10 Tablets

Product code: 213

3235₴ Out of stock

Analogues

Ozempic 1 Rybelsus 3 Semaxen 3

Dosage

Pack size

Active ingredient
Dosage form Tablets
Tablets per pack
Packaging Blisters in a box

Rybelsus 3 mg is an innovative oral hypoglycemic medication belonging to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. The drug is indicated to improve glycemic control in adults with type 2 diabetes mellitus. The active substance is Semaglutide at a dosage of 3 mg. The drug stimulates insulin secretion when blood glucose levels are high, suppresses glucagon release, delays gastric emptying, and reduces appetite, thereby assisting in weight management.

Manufacturer: Novo Nordisk A/S (Denmark). A global leader in diabetes care and development, ensuring the highest standards of quality and cutting-edge biotechnology in endocrinology.

Key Advantages and Features of Rybelsus 3 mg:

  • ✅ Oral GLP-1 Formulation: The first and only tablet form of semaglutide, providing an effective alternative to injectable counterparts.
  • ✅ Effective Glycemic Control: Significantly reduces glycated hemoglobin (HbA1c) and fasting plasma glucose levels.
  • ✅ Weight Management Support: Promotes natural appetite reduction and weight loss in patients with type 2 diabetes.
  • ✅ High Novo Nordisk Quality: Guarantees original Danish manufacturing, advanced research, and rigorous quality control.

Rybelsus 3 mg is manufactured in oral tablet form:

  • Dosage Form and Packaging: 1 blister contains 10 tablets. Original factory packaging contains 1 blister card (10 tablets) or 3 blister cards (30 tablets).
  • Active Substance: Semaglutide — 3 mg per single tablet.
  • Excipients: Salcaprozate sodium (SNAC) — absorption enhancer, microcrystalline cellulose, povidone K90, magnesium stearate.

Pharmacodynamics: Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. It acts as a GLP-1 receptor agonist, selectively binding to and activating GLP-1 receptors. The drug stimulates glucose-dependent insulin secretion from pancreatic beta cells, decreases glucagon hypersecretion, and slows gastric motility, protecting against postprandial glucose spikes.

Pharmacokinetics: Salcaprozate sodium (SNAC) causes a local increase in pH and facilitates the absorption of semaglutide in the stomach. Peak plasma concentration is achieved 1 to 2 hours post-dose. The elimination half-life is approximately 1 week, maintaining steady-state plasma levels with daily administration. Excreted as metabolites via urine and feces.

Rybelsus 3 mg is prescribed by a physician for the following conditions:

  • 🔹 Type 2 Diabetes Mellitus (Monotherapy): In adult patients when diet and exercise alone do not provide adequate glycemic control and metformin is considered inappropriate due to intolerance or contraindications.
  • 🔹 Combination Therapy: In combination with other glucose-lowering medicinal products (metformin, thiazolidinediones, SGLT2 inhibitors, insulin) when glycemic control is insufficient.
  • 🔹 Initiation Phase: The 3 mg dose is used exclusively as an initial adaptation dose for the first 30 days of therapy.

Rybelsus 3 mg is intended strictly for oral administration:

  • 💊 Initial Adaptation Dose: The starting dose is 3 mg (1 tablet) once daily for 30 days. This dose is intended for gastrointestinal adaptation and is not therapeutically effective for glycemic control.
  • ⏱️ Dose Escalation: After 30 days, the dose must be increased to a maintenance dose of 7 mg once daily (if needed, further escalated to 14 mg once daily under medical supervision).
  • ⚠️ Strict Administration Rules: Take the tablet on an empty stomach upon waking, swallowed whole with a small sip of plain water (no more than 120 ml). Wait at least 30 minutes before eating, drinking, or taking other oral medications.

The use of Rybelsus 3 mg is contraindicated in the following conditions:

  • ❌ Hypersensitivity to semaglutide or to any of the excipients.
  • ❌ Personal or family history of medullary thyroid carcinoma (MTC).
  • ❌ Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • ❌ Type 1 diabetes mellitus and treatment of diabetic ketoacidosis.
  • ❌ Severe gastrointestinal disorders (e.g., severe gastroparesis).
  • ❌ Pregnancy and breastfeeding period.

When using Rybelsus 3 mg concurrently with other medicinal products, consider the following factors:

  • ⚠️ Oral Medications: Delayed gastric emptying may affect the rate and extent of absorption of other co-administered oral drugs.
  • ⚠️ Insulin and Sulfonylureas: Increased risk of hypoglycemia; a reduction in the dose of insulin or sulfonylurea may be required.
  • ⚠️ Levothyroxine Sodium: Total exposure of thyroxin may increase by 33% when co-administered (monitoring of thyroid parameters is recommended).

The use of Rybelsus 3 mg during pregnancy and lactation is strictly contraindicated. When planning a pregnancy, discontinuation of the medication at least 2 months in advance is required due to the long half-life of semaglutide. Breastfeeding must be discontinued if therapy becomes necessary.

Side effects of Rybelsus 3 mg occur most frequently in the gastrointestinal system during the initial adaptation period:

  • 🤢 Gastrointestinal System (Very Common): Nausea, diarrhea, vomiting, decreased appetite, dyspepsia, abdominal pain, constipation, flatulence.
  • 📉 Metabolic Disorders: Hypoglycemia (when used in combination with insulin or sulfonylureas).
  • 🧠 Nervous System (Common): Dizziness, fatigue, dysgeusia (taste alteration).
  • 🔬 Laboratory Parameters: Increased lipase and amylase activity, slight increase in heart rate.

Symptoms of Overdose: Severe nausea, persistent vomiting, severe diarrhea, risk of hypoglycemia (especially in combination therapy).

Overdose Treatment: There is no specific antidote. Symptomatic and supportive treatment should be initiated based on clinical manifestations. Prolonged observation is necessary due to the long half-life of semaglutide.

Rules for storing Rybelsus 3 mg:

  • 🌡️ Temperature Regime: Store at temperatures between 15 °C and 30 °C in the original package.
  • 💧 Moisture Protection: Store in the original blister to protect from moisture and light. Do not transfer tablets to other containers.
  • 👶 Safety: Keep safely out of reach of children. Do not use past the expiration date.

To confirm the authenticity of Rybelsus 3 mg, pay attention to the following features:

  • 🛡️ Packaging and Logo: The official logo of Novo Nordisk (Apis bull in a circle) is printed on the front of the box. White-and-green design featuring a yellow-green graphic block with a clear "3 mg" indication.
  • 🔍 Marking: The batch number (Batch No.), date of manufacture (Mfg Date), and expiration date (Exp Date) are embossed or printed on the side of the box and blister.
  • 📦 Tablet and Blister Form: Tablets are packaged in a specialized moisture-barrier blister. Each tablet has a distinct shape and embossing indicating the dosage (3 on one side).

Pack size

Out of stock

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00